Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Sep 22;13:975641. doi: 10.3389/fphar.2022.975641

Future insights of pharmacological prevention for AKI post cardiopulmonary bypass surgery (based on PK/PD approach)

Dias Permeisari 1,*
PMCID: PMC9536004  PMID: 36210841

Abstract

The incidence of acute kidney injury (AKI) post-cardiopulmonary bypass (CPB) can cause an increase in the rate of renal replacement therapy (RRT) and mortality rate. Compared to brain and liver damage post-CPB, AKI has the highest incidence of 83%. Based on this phenomenon, various efforts have been made to reduce the incidence of AKI post-CPB, both pharmacologically and non-pharmacologically interventions. The purpose of this review is to emphasize several renal protector agents which under optimal conditions can provide significant benefits in reducing the incidence of AKI post-CPB. This article was obtained by conducting a study on several kinds of literature, including the original article, RCT study, systematic review and meta-analysis, and other review articles. There are five renal protector agents that are the focus of this article, those are fenoldopam which effectively works to prevent the incidence of AKI post-CPB, while furosemide has shown satisfactory results in patients with decreased renal function when administered in the Renal Guard (RG) system, mannitol, and nitric oxide, both of these can also effectively reduce the incidence of AKI post‐CPB by controlling its blood concentration and timing of administration, and another form of N-Acetylcysteine, namely N‐Acetylcysteine amide has better activity as a renoprotective agent than N‐Acetylcysteine itself. The benefits of these agents can be obtained by developing devices that can control drug levels in the blood and create optimal conditions for drugs during the use of a CPB machine.

Keywords: AKI post-CPB, pharmacological intervention, technological improvement, PK/PD approach, pk profile-related CPB

Highlights

  • •  In addition to the problem of dosage, the selection of drugs that are in accordance with the patient’s condition and the time of administration is a crucial to get the benefits of a drug

  • •  The use of a CPB machine can affect the pharmacokinetic parameters of a drug, including drug levels in the blood, and this will also affect the effectiveness of the drug, thus requiring device development that can control drug levels in the blood and adjust the dose during CPB

  • •  Renoprotective agent can turn into a nephrotoxin if it exceeds the effective range of drug levels in the blood

Introduction

Based on a clinical study that has been conducted, the incidence of acute kidney injury after cardiac surgery is the most common adverse outcome with an incidence rate of up to 83% by the AKIN and KDIGO criteria (da Silva et al., 2021), when it compared to the prevalence of brain injury was 20% and for acute liver injury in the first 48 h was 0.77% (Tachibana et al., 2021; Zakeri et al., 2021). Afterward, the definition of AKI which is used in this review is in accordance with the KDIGO criteria, characterized by an increase in serum creatinine (SCr) 0.3 mg/dl within 48 h and a decrease in urine output (UO) < 0.5 ml/kg every hour for 6 h. Generally, the incidence of AKI might occur after cardiac surgery as a consequence of CPB utilization. In a retrospective study involved 3889 patients, present a correlation between duration use of CPB and incidence of acute kidney injury after cardiac surgery (Axtell et al., 2020), it was part of the intraoperative factors that causes incidence of AKI post-CPB through several mechanisms of action, namely hemodynamic perturbation, mechanical factors, oxygen delivery, carbon dioxide production, and inflammation (de Somer et al., 2011). In addition to those intraoperative factors, there is another condition of preoperative factor that also possible to increase the incidence of AKI post-CPB which commonly caused by the presence of pre-existing kidney disease (Alramadan et al., 2019), pulmonary disease, obesity (Thakar et al., 2005; Fu et al., 2021) and older age (Thakar et al., 2005; Chronopoulos et al., 2010). Various strategies were made to prevent incidence of AKI related to CPB utilization. The preventive strategies for AKI post-CPB can be classified into two, those are the pharmacological and non-pharmacological intervention (Ostermann et al., 2021). Based on several studies that have been conducted, including randomized controlled trial (RCT), review article, and systematic review and meta-analysis, only a few numbers of these pharmacological interventions may provide promising results in reducing the risk of developing AKI post-CPB (Buylaert et al., 1989; Yang et al., 2014; Gillies et al., 2015; Hu et al., 2019; Krawczeski Catherine, 2019).

Furosemide

Furosemide is a loop diuretic that works by decreasing the activity of the sodium-potassium-chloride cotransporter in the apical membrane of the tubular epithelial cells in the thick ascending loop of Henle so as to reduce the medullary net oxygen consumption (Khan et al., 2022). On the other hand, furosemide administration can also cause volume depletion and possibly renal hypoperfusion (Ho and Power, 2010). In anuric patients, furosemide administration becomes ineffective because in that condition glomerular filtration stops, so furosemide becomes completely inactive (Patschan et al., 2019). Based on a study conducted by Zhao et al, showed that furosemide can reduce in-hospital mortality and improve renal function recovery in patients with AKI urine output (UO) stage 2–3, however furosemide administration in patients with AKI SCr stage 2–3 and chronic kidney disease become ineffective (Zhao et al., 2020). One strategy to achieve optimal conditions for the mechanism of furosemide as a renoprotective agent by maintaining fluid balance is to carry out technological improvements of device such as the Renal Guard (RG) System (Barbanti et al., 2015; Luckraz et al., 2017; Katoh et al., 2019; Luckraz et al., 2021). The results in Table 1.

TABLE 1.

Evidences of renal guard system utilization for AKI prevention.

Study, year Type of surgery Study design Dosage regimens Results
Luckraz et al. (2017) Cardiac surgery Prospective, observational 20 mg, 90 min preprocedure-during procedure-4 h after last contrast inj No patients developed AKI within 36 h of surgery
Luckraz et al. (2021) Cardiac surgery RCT 20 mg initiated, cont.10 mg/h, Start after intubation until 6 h after CICU admission Reduced AKI incidence, increases urine output within 24 h of surgery
Barbanti et al. (2015) Transcatheter aortic valve replacement RCT 0.25 mg/kg after priming- cont.during procedure-4 h thereafter Reduced AKI incidence rate
Katoh et al. (2019) PCI Prospective, observational 0.25 mg/kg, controlled during procedure up to 4 h thereafter Prevent CI-AKI in Japanese patient with renal dysfunction
Open in a new tab

Mannitol

Mannitol is a sugar alcohol and isomer of sorbitol so it has a sweet taste. Mannitol can be used as an osmotic diuretic and hypertonic solution which is often implemented in several clinical settings, such as crush injury, compartment syndrome, intraocular and intracranial hypertension. Mannitol has a small molecular weight that can be easily filtered at the glomerulus which then possible to reduce water reabsorption in the proximal tubule and sodium concentration. The implementation of mannitol in clinical settings has a large dose variation, as a result it can be more difficult to determine the optimal dose of mannitol use (Fandino, 2017). The mechanism of mannitol as a renal vasodilator is produced at low doses, whereas mannitol actually produces the opposite effect as a renal vasoconstrictor at high doses of administration. Acute renal failure (ARF) is very likely to occur upon administration of high doses of mannitol, where it means over than 200 g per day or cumulative dose >400 g in 48 h (Gadallah et al., 1995). Administration of mannitol in patients who have demonstrated pre-existing kidney impairment will lead to a greater potential for nephrotoxicity due to the accumulation of mannitol (Visweswaran et al., 1997). The incidence of nephrotoxicity may be caused by the use of mannitol at high serum levels (>1,000 mg/dl) in which the clinical condition can be signed by the increasing of osmolality calculated by the osmolal gap. An osmolal gap value of more than 55 mOsm/kg is very possible to increase the risk of acute kidney injury (Dorman et al., 1990; Pérez-Pérez et al., 2002; Mary et al., 2021).

Fenoldopam

Fenoldopam is a short acting selective agonist of dopamine-1 receptors that can reduce systemic vascular resistance and improve renal blood flow which is generally used as an antihypertensive (Nichols et al., 1990). Besides the clinical benefit, fenoldopam also has a potent agonist effect on DA1 receptors when compared to dopamine (Murphy and ClareShorten, 2001). Both of fenoldopam and dopamine are included in dopamine receptor members that belong to G-protein-coupled receptor superfamily. The outline classification of dopamine receptor is divided in two categories, namely D1 and D2 which are located in the central nervous system and have the ability to stimulate (D1) or inhibit (D2) adenylate cyclase (Nichols et al., 1990). While the peripheral dopamine-1 receptor sites are located on blood vessels, renal tubules, and juxtaglomerular cells. At low doses, fenoldopam has a direct effect on the renal tubules which it has ability to produce natriuresis and diuresis (Ricci and Ronco, 2006) and at the renal dose, fenoldopam has no any systemic effects (Ricci and Ronco, 2006; Noce et al., 2019). In a small study, it was shown that fenoldopam exerted positive result by increasing blood flow in all renal compartments and the amelioration of renal blood flow produced in starting from a dose of 0.1–0.3 μg/kg/min with stable hemodynamic conditions of patients and preserved renal function (Meco and Cirri, 2010). Administration of fenoldopam did not provide any benefit to patient which may experience deterioration in mean arterial pressure during cardiac surgery and in the presence of insufficient of renal function. Thereby the use of fenoldopam is appropriate for the prevention strategy of postoperative AKI (Meco and Cirri, 2010; Noce et al., 2019).

Nitric Oxide

Nitric oxide (NO) is an antioxidant and an important homeostatic mediator of renal hemodynamics. Administration of exogenous nitric oxide in CPB may be useful for maintaining organ perfusion and vasodilation due to increased release of free Hb caused by red blood cells in contact with the bypass circuit, in addition to prevent glomerular injury due to reactive oxygen species (Khorashadi et al., 2020). In an RCT study involving 244 subjects, nitric oxide administration of 80 parts per million via gas exchanger on a CPB machine followed by inhalation route for 48 h post-operative, nitric oxide can effectively reduce the incidence of AKI post-operative during the first year completion of surgery (Lei et al., 2018). In another study showed, a systematic review and meta-analysis of NO used in patients who underwent CPB is giving a promising in preventing incidence of AKI post-CPB, however it remained need further investigations to determine the time of administration and dosage regimens (Hu et al., 2019).

N-Acetylcysteine

N-acetylcysteine (NAC) is commonly used as a mucolytic agent since its discovery several decades ago, in addition to its use as a treatment for acetaminophen toxicity. However, with the development of research in the field of pharmacology, NAC which acts as an antioxidant by reducing or even preventing oxidative stress and as a scavanger of reactive oxygen species is also used to protect kidney function and is used in the field of cardiology (Samuni et al., 2013; Pedre et al., 2021). Based on a study conducted on animals, present a form of NAC amide (NACA) which has better activity as a renoprotective agent when compared to NAC itself by upregulating thioredoxin-1 and inhibition of signal-regulating kinase 1 (ASK1) which is an activator of the p38MAPK pathway in inhibiting apoptosis of renal cells, consequently it can significantly reduce serum creatinine elevation, blood urea nitrogen, biomarkers of AKI, and prevent histologic changes resulting from renal tubular injuries (Gong et al., 2016). A pharmacokinetic study of NAC, showed that there was a significant decrease in NAC clearance of up to 90% when oral NAC was administered to patients with end-stage renal disease (ESRD), although plasma NAC levels increased dose-related (Nolin et al., 2010). The clinical use of NAC in an attempt to reduce the risk of AKI postcardiac surgery can effectively reduce the incidence of AKI based on the evidence in a systematic review and meta-analysis study, but not for all-causes of mortality and the patient’s need of RRT with high-dose intravenous NAC during the perioperative period (Tan et al., 2022; Zhao et al., 2022).

Alteration pharmacokinetic of drugs related post-cardiopulmonary bypass utilization

In surgical procedures that use CPB, lung and heart functions are maintained by an instrument, namely the CPB machine. The use of CPB is possible to change the pharmacokinetic profile and serum concentration of drugs used during on-pump. Some of the pharmacokinetic parameters that have changed are distribution, hepatic, and renal elimination resulted by several mechanisms, namely hemodilution due to the addition of pump priming solution before initiation of CPB, coupled with low pump flow rate which causes a decrease in mean arterial pressure (MAP) resulting in changes in regional flow distribution is characterized by decline in perfusion of several organs, including several vital organs. During the use of CPB, occurrence of hypothermia may affect in decreasing of metabolic requirements (Buylaert et al., 1989).

Future insight of technological improvement

Modification of drug delivery aims to achieve the therapeutic target as desired, which cannot be achieved by conventional methods. In administering drugs via intravenous injection as an infusion, modification of drug delivery can be through targeted delivery systems devices and the PK/PD approach by determining the effective plasma concentration, considering the volume of distribution, hepatic and renal elimination, and the compartmental model, in attempt to prevent accumulation of drugs which is given by infusion (Shargel et al., 2012). Enhancing device technology of drug administration, drug plasma concentrations targeted and controlled, provide feedback with high precision as the mechanism of sensors, and have capability of doses adjustment to fill the individually requirement would become a powerful tool in pharmacological research and clinical practice such as an in-vivo study that conducted by Netzahualcoyotl et al (Arroyo-Currás et al., 2018).

Conclusion

AKI is the most common complication after cardiac surgery with CPB. The occurrence of AKI can provide a poor outcome in patients and can increase the mortality rate. Various efforts have been made to prevent the occurrence of AKI post-CPB, the focus of this article is the pharmacological strategy for the prevention of AKI, where there are four types of drugs that can work effectively by considering the patient’s physiology and the device to achieve the proper drug plasma concentration.

Acknowledgments

The author sincerely acknowledges the perfusionist of Anesthesiology and Reanimation Department at Soetomo General Hospital, Indonesia, for the support in giving information of CPB during surgery, allowing the author to participate in the operating room, and providing some references of CPB mechanisms to author.

Author contributions

The author confirms being the sole contributor of this work and has approved it for publication.

Conflict of interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Alramadan M. J., Karim M. N., Hossain M. N., Smith J. A., Cochrane A., Reid C. M., et al. (2019). Renal disease is associated with poor outcomes following isolated coronary artery bypass grafting. Glob. Heart 14 (4), 347–353. 10.1016/j.gheart.2019.08.002 [DOI] [PubMed] [Google Scholar]
  2. Arroyo-Currás N., Ortega G., Copp D. A., Ploense K. L., Plaxco Z. A., Kippin T. E., et al. (2018). High-precision control of plasma drug levels using feedback-controlled dosing. ACS Pharmacol. Transl. Sci. 1 (2), 110–118. 10.1021/acsptsci.8b00033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Axtell A. L., Fiedler A. G., Melnitchouk S., D'Alessandro D. A., Villavicencio M. A., Jassar A. S., et al. (2020). Starting elective cardiac surgery after 3 pm does not impact patient morbidity, mortality, or hospital costs. J. Thorac. Cardiovasc. Surg. 159 (1), 2314–2321.e2. 10.1016/j.jtcvs.2019.06.12510.1016/j.jtcvs.2019.01.072 [DOI] [PubMed] [Google Scholar]
  4. Barbanti M., Gulino S., Capranzano P., Immè S., Sgroi C., Tamburino C., et al. (2015). Acute kidney injury with the RenalGuard system in patients undergoing transcatheter aortic valve replacement: The PROTECT-TAVI trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in transcatheter aortic valve implantation). JACC. Cardiovasc. Interv. 8 (12), 1595–1604. 10.1016/j.jcin.2015.07.012 [DOI] [PubMed] [Google Scholar]
  5. Buylaert W. A., Herregods L. L., Mortier E. P., Bogaert M. G. (1989). Cardiopulmonary bypass and the pharmacokinetics of drugs. An update. Clin. Pharmacokinet. 17, 10–26. 10.2165/00003088-198917010-00002 [DOI] [PubMed] [Google Scholar]
  6. Chronopoulos A., Rosner M. H., Cruz D. N., Ronco C. (2010). Acute kidney injury in elderly intensive care patients: A review. Intensive Care Med. 36, 1454–1464. 10.1007/s00134-010-1957-7 [DOI] [PubMed] [Google Scholar]
  7. da Silva T. F., da Cruz Silva K. R., Nepomuceno C. M., Maruri Corrêa C. S., Mello Godoy J. P., dos Santos A. T. L., et al. (2021). Incidence of acute kidney injury post cardiac surgery: A comparison of the AKIN and KDIGO criteria. Braz. J. Anesthesiol. 71 (5), 511–516. 10.1016/j.bjane.2021.02.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. de Somer F., Mulholland J. W., Bryan M. R., Aloisio T., Van Nooten G. J., Ranucci M. (2011). O2 delivery and CO2 production during cardiopulmonary bypass as determinants of acute kidney injury: Time for a goal-directed perfusion management? Crit. Care 15 (4), R192. 10.1186/cc10349 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dorman H. R., Sondheimer J. H., Cadnapaphornchai P. (1990). Mannitol-induced acute renal failure. Medicine 69 (3), 153–159. 10.1097/00005792-199005000-00003 [DOI] [PubMed] [Google Scholar]
  10. Fandino Wilson. (2017). Understanding the physiological changes induced by mannitol: From the theory to the clinical practice in neuroanaesthesia. J. Neuroanaesth. Crit. Care 4, 138. 10.4103/jnacc.jnacc_31_17 [DOI] [Google Scholar]
  11. Fu Hsun-Yi, Chou Nai-Kuan, Chen Yih-Sharng, Yu Hsi-Yu. (2021). Risk factor for acute kidney injury in patients with chronic kidney disease receiving valve surgery with cardiopulmonary bypass. Asian J. Surg. 44 (1), 229–234. 10.1016/j.asjsur.2020.05.024 [DOI] [PubMed] [Google Scholar]
  12. Gadallah M. F., Lynn M., Work J. (1995). Case report: Mannitol nephrotoxicity syndrome: Role of hemodialysis and postulate of mechanisms. Am. J. Med. Sci. 309 (4), 219–222. 10.1097/00000441-199504000-00006 [DOI] [PubMed] [Google Scholar]
  13. Gillies M. A., Kakar V., Parker R. J., Honoré P. M., Ostermann M. (2015). Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis. Crit. Care 19, 449. 10.1186/s13054-015-1166-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gong X., Duan Y., Zheng J., Wang Y., Wang G., Norgren S., et al. (2016). Nephroprotective effects of N-acetylcysteine amide against contrast-induced nephropathy through upregulating thioredoxin-1, inhibiting ASK1/p38MAPK pathway, and suppressing oxidative stress and apoptosis in rats. Oxid. Med. Cell. Longev. 2016, 8715185. 10.1155/2016/8715185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ho K. M., Power B. M. (2010). Benefits and risks of furosemide in acute kidney injury. Anaesthesia 65 (3), 283–293. 10.1111/j.1365-2044.2009.06228.x [DOI] [PubMed] [Google Scholar]
  16. Hu J., Spina S., Zadek F., Kamenshchikov N. O., Bittner E. A., Pedemonte J., et al. (2019). Effect of nitric oxide on postoperative acute kidney injury in patients who underwent cardiopulmonary bypass: A systematic review and meta-analysis with trial sequential analysis. Ann. Intensive Care 9, 129. 10.1186/s13613-019-0605-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Katoh H., Nozue T., Horie K., Sozu T., Inoue N., Michishita I. (2019). RenalGuard system to prevent contrast-induced acute kidney injury in Japanese patients with renal dysfunction; RESPECT KIDNEY study. Cardiovasc. Interv. Ther. 34 (2), 105–112. 10.1007/s12928-018-0527-8 [DOI] [PubMed] [Google Scholar]
  18. Khan T. M., Patel R., Siddiqui A. H. (2022). Furosemide. Treasure Island: StatPearls. [Google Scholar]
  19. Khorashadi M., Bokoch M. P., Legrand M. (2020). Is nitric oxide the forgotten nephroprotective treatment during cardiac surgery? Ann. Intensive Care 10, 22. 10.1186/s13613-020-0631-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Krawczeski Catherine D. (2019). Cardiopulmonary bypass and AKI: AKI is bad, so let's get beyond the diagnosis. Front. Pediatr. 7, 492. 10.3389/fped.2019.00492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lei C., Berra L., Rezoagli E., Yu B., Dong H., Yu S., et al. (2018). Nitric oxide decreases acute kidney injury and stage 3 chronic kidney disease after cardiac surgery. Am. J. Respir. Crit. Care Med. 198 (10), 1279–1287. 10.1164/rccm.201710-2150OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shargel L., Wu-Pong S., Yu A. C. (Editors) (2012). Applied Biopharmaceutics & Pharmacokinetics, 6e (New York, New York, United States: McGraw-Hill; ). [Google Scholar]
  23. Luckraz H., Giri R., Wrigley B., Hennessy A. M., Nicholas J., Nevill A. (2017). The use of the RenalGuard system in cardiac surgery with cardiopulmonary bypass: A first in man prospective, observational, feasibility pilot study. Open Heart 4, e000669. 10.1136/openhrt-2017-000669 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Luckraz H., Giri R., Wrigley B., Nagarajan K., Senanayake E., Sharman E., et al. (2021). Reduction in acute kidney injury post cardiac surgery using balanced forced diuresis: A randomized, controlled trial. Eur. J. Cardiothorac. Surg. 59, 562–569. 10.1093/ejcts/ezaa395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mary G., Paul Geo A. J., Varada A., Muhammad Afzal C. M., Joy Breeze Ann. Ajmal Nalakathkarappamveetil Muthu (2021). Incidence and determinants of acute kidney injury following Mannitol therapy. MGM J. Med. Sci. 8, 355–360. 10.4103/mgmj.mgmj_46_21 [DOI] [Google Scholar]
  26. Meco M., Cirri S. (2010). The effect of various fenoldopam doses on renal perfusion in patients undergoing cardiac surgery. Ann. Thorac. Surg. 89 (2), 497–503. 10.1016/j.athoracsur.2009.09.071 [DOI] [PubMed] [Google Scholar]
  27. Murphy Michael B. Murray, ClareShorten George D. (2001). Fenoldopam — a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N. Engl. J. Med. 345, 1548–1557. 10.1056/NEJMra010253 [DOI] [PubMed] [Google Scholar]
  28. Nichols A. J., Ruffolo R. R., Jr, Brooks D. P. (1990). The pharmacology of fenoldopam. Am. J. Hypertens. 3 (2), 116S–119S. 10.1093/ajh/3.6.116s [DOI] [PubMed] [Google Scholar]
  29. Noce A., Marrone G., Rovella V., Busca A., Gola C., Ferrannini M., et al. (2019). Fenoldopam mesylate: A narrative review of its use in acute kidney injury. Curr. Pharm. Biotechnol. 20 (5), 366–375. 10.2174/1389201020666190417124711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nolin T. D., Ouseph R., Himmelfarb J., McMenamin M. E., Ward R. A. (2010). Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin. J. Am. Soc. Nephrol. 5 (9), 1588–1594. 10.2215/CJN.00210110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ostermann M., Kunst G., Baker E., Weerapolchai K., Lumlertgul N. (2021). Cardiac surgery associated AKI prevention strategies and medical treatment for CSA-AKI. J. Clin. Med. 10 (22), 5285. 10.3390/jcm10225285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Patschan D., Patschan S., Buschmann I., Ritter O. (2019). Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press. Res. 44, 457–464. 10.1159/000501315 [DOI] [PubMed] [Google Scholar]
  33. Pedre B., Barayeu U., Ezeriņa D., Dick T. P. (2021). The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species. Pharmacol. Ther. 228, 107916. 10.1016/j.pharmthera.2021.107916 [DOI] [PubMed] [Google Scholar]
  34. Pérez-Pérez A, J., Pazos B., Sobrado J., Gonzalez L., Gándara A. (2002). Acute renal failure following massive mannitol infusion. Am. J. Nephrol. 22, 573–575. 10.1159/000065279 [DOI] [PubMed] [Google Scholar]
  35. Ricci Z., Ronco C. (2006). Renal-dose' fenoldopam for early-stage renal dysfunction in critically ill patients. Nat. Clin. Pract. Nephrol. 2, 548–549. 10.1038/ncpneph0284 [DOI] [PubMed] [Google Scholar]
  36. Samuni Y., Goldstein S., Dean O. M., Berk M. (2013). The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta 1830 (8), 4117–4129. 10.1016/j.bbagen.2013.04.016 [DOI] [PubMed] [Google Scholar]
  37. Tachibana H., Hiraoka A., Saito K., Naito Y., Chikazawa G., Tamura K., et al. (2021). Incidence and impact of silent brain lesions after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 161 (2), 636–644. 10.1016/j.jtcvs.2019.09.162 [DOI] [PubMed] [Google Scholar]
  38. Tan Y. K., Luo H., Kang G. S., Teoh K. L., Kofidis T. (2022). N-Acetylcysteine's renoprotective effect in cardiac surgery: A systematic review and meta-analysis. Ann. Thorac. Cardiovasc. Surg. 28 (2), 138–145. 10.5761/atcs.oa.21-00132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Thakar C. V., Arrigain S., Worley S., Yared J. P., Paganini E. P. (2005). A clinical score to predict acute renal failure after cardiac surgery. J. Am. Soc. Nephrol. 16 (1), 162–168. 10.1681/ASN.2004040331 [DOI] [PubMed] [Google Scholar]
  40. Visweswaran P., Massin E. K., Dubose T. D., Jr (1997). Mannitol-induced acute renal failure. J. Am. Soc. Nephrol. 8 (6), 1028–1033. 10.1681/ASN.V861028 [DOI] [PubMed] [Google Scholar]
  41. Yang B., Xu J., Xu F., Zou Z., Ye C., Mei C., et al. (2014). Intravascular administration of mannitol for acute kidney injury prevention: A systematic review and meta-analysis. PloS one 9 (1), e85029. 10.1371/journal.pone.0085029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zakeri S., Vafaey H., Banihashem N., Alijanpour A., Gholinia H., Behzad C. (2021). Evaluation of liver function tests after coronary artery bypass surgery (CABG). Casp. J. Intern. Med. 12 (1), 45–52. 10.22088/cjim.12.1.45 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Zhao G. J., Xu C., Ying J. C., Lü W. B., Hong G. L., Li M. F., et al. (2020). Association between furosemide administration and outcomes in critically ill patients with acute kidney injury. Crit. Care 24 (1), 75. 10.1186/s13054-020-2798-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zhao J., Li M., Tan C. (2022). Efficacy of N-acetylcysteine in preventing acute kidney injury and major adverse cardiac events after cardiac surgery: A meta-analysis and trial sequential analysis. Front. Med. 9, 795839. 10.3389/fmed.2022.795839 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES